Es gab 50 kürzliche Insider-Transaktionen für Brainstorm Cell Therapeutics Inc. (BCLI), darunter 44 Käufe und 1 Verkauf. Die gesamten Insider-Käufe beliefen sich auf $575.32K und die gesamten Insider-Verkäufe auf $22.07K.
Bedeutende Insider mit kürzlicher Aktivität umfassen Hartounian Hartoun, Frenkel Jacob A, Arbel Irit. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — BCLI
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2025-01-01 |
Hartounian Hartoun |
EVP, Chief Operating Officer |
RSU-Zuteilung |
50,000 |
- |
- |
52,000 |
| 2025-01-01 |
Frenkel Jacob A |
Director |
RSU-Zuteilung |
40,000 |
- |
- |
43,777 |
| 2025-01-01 |
Arbel Irit |
Director |
RSU-Zuteilung |
30,666 |
- |
- |
41,054 |
| 2025-01-01 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
120,000 |
- |
- |
200,960 |
| 2025-01-01 |
Yablonka Uri |
EVP & Chief Business Officer |
RSU-Zuteilung |
40,000 |
- |
- |
48,464 |
| 2025-01-01 |
Patlis Alla |
See Remarks |
RSU-Zuteilung |
40,000 |
- |
- |
44,349 |
| 2025-01-01 |
Polverino Anthony J. |
Director |
RSU-Zuteilung |
24,000 |
- |
- |
25,730 |
| 2025-01-01 |
Lindborg Stacy |
Director |
RSU-Zuteilung |
20,000 |
- |
- |
48,229 |
| 2025-01-01 |
Bairu Menghisteab |
Director |
RSU-Zuteilung |
24,000 |
- |
- |
24,000 |
| 2025-01-01 |
Naor Nir |
Director |
RSU-Zuteilung |
30,666 |
- |
- |
31,465 |
| 2025-01-01 |
Dagher Ibrahim B. |
Chief Medical Officer |
RSU-Zuteilung |
50,000 |
- |
- |
66,849 |
| 2024-10-01 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
1,836 |
$3.43 |
$6.29K |
80,960 |
| 2024-09-30 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
22,000 |
$0.23 |
$5.02K |
1,186,865 |
| 2024-07-19 |
Dagher Ibrahim B. |
Chief Medical Officer |
Informierter Verkauf |
63,000 |
$0.35 |
$22.07K |
- |
| 2024-06-24 |
Hartounian Hartoun |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-06-24 |
Hartounian Hartoun |
EVP, Chief Operating Officer |
RSU-Zuteilung |
30,000 |
- |
- |
30,000 |
| 2024-05-28 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
15,000 |
$0.52 |
$7.77K |
1,164,865 |
| 2024-05-28 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
15,000 |
$0.52 |
$7.77K |
1,164,865 |
| 2024-05-22 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
25,000 |
$0.64 |
$16K |
1,149,865 |
| 2024-05-22 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
25,000 |
$0.64 |
$16K |
1,149,865 |
| 2024-05-21 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
25,000 |
$0.58 |
$14.48K |
1,124,865 |
| 2024-05-21 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
25,000 |
$0.58 |
$14.48K |
1,124,865 |
| 2024-05-13 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
10,000 |
$0.49 |
$4.9K |
1,099,865 |
| 2024-05-13 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
10,000 |
$0.49 |
$4.9K |
1,099,865 |
| 2024-05-11 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
10,000 |
$0.47 |
$4.67K |
1,089,865 |
| 2024-05-11 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
10,000 |
$0.47 |
$4.67K |
1,089,865 |
| 2024-05-10 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
20,000 |
$0.47 |
$9.3K |
1,079,865 |
| 2024-05-10 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
20,000 |
$0.47 |
$9.3K |
1,079,865 |
| 2024-05-07 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
66,300 |
$0.37 |
$24.82K |
1,059,865 |
| 2024-05-07 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
66,300 |
$0.37 |
$24.82K |
1,059,865 |
| 2024-05-06 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
135,000 |
$0.38 |
$50.67K |
993,565 |
| 2024-05-06 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
135,000 |
$0.38 |
$50.67K |
993,565 |
| 2024-04-19 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
15,000 |
$0.52 |
$7.8K |
858,565 |
| 2024-04-19 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
15,000 |
$0.52 |
$7.8K |
858,565 |
| 2024-04-18 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
115,072 |
$0.53 |
$60.47K |
843,565 |
| 2024-04-18 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
115,072 |
$0.53 |
$60.47K |
843,565 |
| 2024-04-17 |
Dagher Ibrahim B. |
Chief Medical Officer |
Unbekannt |
80,000 |
$1.73 |
$138.4K |
- |
| 2024-04-17 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
130,000 |
$0.55 |
$70.94K |
728,493 |
| 2024-04-17 |
Dagher Ibrahim B. |
Chief Medical Officer |
Unbekannt |
- |
- |
- |
30,000 |
| 2024-04-17 |
Lebovits Chaim |
President & CEO |
Informierter Kauf |
130,000 |
$0.55 |
$70.94K |
728,493 |
| 2024-03-11 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
305,198 |
- |
- |
598,493 |
| 2024-03-11 |
Yablonka Uri |
EVP & Chief Business Officer |
RSU-Zuteilung |
109,426 |
- |
- |
126,969 |
| 2024-03-11 |
Patlis Alla |
See Remarks |
RSU-Zuteilung |
65,246 |
- |
- |
65,246 |
| 2024-03-11 |
Lindborg Stacy |
Co-chief Executive Officer |
RSU-Zuteilung |
241,935 |
- |
- |
423,435 |
| 2023-09-01 |
Lindborg Stacy |
Co-chief Executive Officer |
Informierter Kauf |
11,500 |
$1.77 |
$20.4K |
181,500 |
| 2023-08-02 |
Lebovits Chaim |
President & CEO |
RSU-Zuteilung |
31,185 |
- |
- |
293,295 |
| 2023-08-02 |
Lindborg Stacy |
Co-chief Executive Officer |
RSU-Zuteilung |
35,000 |
- |
- |
170,000 |
| 2023-06-19 |
Naor Nir |
Director |
Unbekannt |
- |
- |
- |
- |
| 2023-06-19 |
Naor Nir |
Director |
RSU-Zuteilung |
11,999 |
- |
- |
11,999 |
| 2023-05-01 |
Taylor Kirk |
Officer |
Unbekannt |
- |
- |
- |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
